Home / Market News / $RFL
fiscal.ai Corporate Catalyst Impact 65/100 ● negative

Rafael Holdings Reports Fiscal 2026 Financial Results

Oct 30, 2026, 1:16 PM UTC · Primary ticker $RFL

Rafael Holdings reported a full fiscal year 2026 net loss of $29.6 million, a slight improvement from the prior year. The company's cash and cash equivalents stood at $22.1 million, while R&D expenses significantly increased due to subsidiary Cyclo Therapeutics.

Rafael Holdings (RFL) reported a net loss of $29.6 million for fiscal year 2026, a marginal improvement from the previous year. While the Q4 loss narrowed due to reduced G&A expenses, a significant increase in R&D spending, primarily at its subsidiary Cyclo Therapeutics (CYTH), led to higher overall R&D costs. The company's cash position of $22.1 million as of July 31, 2026, is a key concern given the ongoing losses and increased R&D burn. This filing indicates continued operational losses and a potentially limited cash runway, which could necessitate future financing. For traders, the short-term implication is likely negative for RFL due to the persistent losses and cash burn, while CYTH's increased R&D could be seen as a long-term opportunity if it leads to successful drug development, but also a short-term drain on RFL's resources.

$RFL negative Continued net losses, increased R&D spend, limited cash runway
$CYTH neutral Increased R&D spending at subsidiary, indicating active development
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.